Terms: = Breast cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Treatment
808 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models.
Rypens C; Van Berckelaer C; Berditchevski F; van Dam P; Van Laere S
Int Rev Cell Mol Biol; 2024; 384():77-112. PubMed ID: 38637101
[TBL] [Abstract] [Full Text] [Related]
3. Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative breast cancer.
Fan T; Huang Y; Liu Z; Huang J; Ke B; Rong Y; Qiu H; Zhang B
Drug Des Devel Ther; 2024; 18():1115-1131. PubMed ID: 38618280
[TBL] [Abstract] [Full Text] [Related]
4. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
[TBL] [Abstract] [Full Text] [Related]
5. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
Lin CJ; Jin X; Ma D; Chen C; Ou-Yang Y; Pei YC; Zhou CZ; Qu FL; Wang YJ; Liu CL; Fan L; Hu X; Shao ZM; Jiang YZ
Cancer Cell; 2024 Apr; 42(4):701-719.e12. PubMed ID: 38593782
[TBL] [Abstract] [Full Text] [Related]
6. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R; De Sanctis R; Jacobs F; Benvenuti C; Gaudio M; Saltalamacchia G; Torrisi R; Masci G; Miggiano C; Agustoni F; Pedrazzoli P; Santoro A; Zambelli A
Crit Rev Oncol Hematol; 2024 Apr; 196():104324. PubMed ID: 38462150
[TBL] [Abstract] [Full Text] [Related]
7. Cytoplasmic localization of SETDB1‑induced Warburg effect via c‑myc‑LDHA axis enhances migration and invasion in breast carcinoma.
Yang W; Wei Y; Wang T; Xu Y; Jin X; Qian H; Yang S; He S
Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38426579
[TBL] [Abstract] [Full Text] [Related]
8. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and myc Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive breast cancer.
Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
[TBL] [Abstract] [Full Text] [Related]
9. Therapeutic interventions on human breast cancer xenografts promote systemic dissemination of oncogenes.
Raghuram GV; Pal K; Sriram G; Khan A; Joshi R; Jadhav V; Shinde S; Shaikh A; Rane B; Kangne H; Mittra I
PLoS One; 2024; 19(2):e0298042. PubMed ID: 38346047
[TBL] [Abstract] [Full Text] [Related]
10. The radiation- and chemo-sensitizing capacity of diclofenac can be predicted by a decreased lactate metabolism and stress response.
Schwab M; Dezfouli AB; Khosravi M; Alkotub B; Bauer L; Birgani MJT; Multhoff G
Radiat Oncol; 2024 Jan; 19(1):7. PubMed ID: 38229111
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.
Ido M; Fujii K; Mishima H; Kubo A; Saito M; Banno H; Ito Y; Goto M; Ando T; Mouri Y; Kousaka J; Imai T; Nakano S
BMC Cancer; 2024 Jan; 24(1):85. PubMed ID: 38229073
[TBL] [Abstract] [Full Text] [Related]
12. Bruceine D and Narclasine inhibit the proliferation of breast cancer cells and the prediction of potential drug targets.
Chen X; Li H
PLoS One; 2024; 19(1):e0297203. PubMed ID: 38215156
[TBL] [Abstract] [Full Text] [Related]
13. Combinational therapy with myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells.
Johari B; Parvinzad Leilan M; Gharbavi M; Mortazavi Y; Sharafi A; Rezaeejam H
Oncol Res; 2023; 32(2):309-323. PubMed ID: 38186581
[TBL] [Abstract] [Full Text] [Related]
14. RTKN2 knockdown alleviates the malignancy of breast cancer cells by regulating the Wnt/β-catenin pathway.
Zhang X; Wang J; Li H
Sci Rep; 2023 Dec; 13(1):23023. PubMed ID: 38155217
[TBL] [Abstract] [Full Text] [Related]
15. Ultrasound-responsive spherical nucleic acid against c-myc/PD-L1 to enhance anti-tumoral macrophages in triple-negative breast cancer progression.
Wang R; Li G; Gao F; Xu F; Li X; Zhang J; Li J; Guan X
Sci China Life Sci; 2024 Apr; 67(4):698-710. PubMed ID: 38151609
[TBL] [Abstract] [Full Text] [Related]
16. Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/β-catenin signaling pathway in breast cancer.
Xu S; Shi Y; Li S
Cancer Chemother Pharmacol; 2024 Mar; 93(3):191-202. PubMed ID: 38051377
[TBL] [Abstract] [Full Text] [Related]
17.
Samandari-Bahraseman MR; Ismaili A; Esmaeili-Mahani S; Ebrahimie E; Loit E
Anticancer Agents Med Chem; 2024; 24(3):213-223. PubMed ID: 38038013
[TBL] [Abstract] [Full Text] [Related]
18. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
Kim SL; Choi HS; Lee DS
Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
[TBL] [Abstract] [Full Text] [Related]
19. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
[TBL] [Abstract] [Full Text] [Related]
20. Tumor Profiles of Late Presentation Uveal Ring Melanoma With Novel Characteristics - A Case Series.
Lim JZ; Crawford AZ; McGhee CNJ
Invest Ophthalmol Vis Sci; 2023 Oct; 64(13):44. PubMed ID: 37889509
[TBL] [Abstract] [Full Text] [Related]
[Next]
